


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A pharmaceutical liquid composition comprising ~~as an active ingredient~~ a pyridone derivative represented by the following formula (I):



wherein R¹ is an alkyl group optionally having a substituent selected from the group consisting of a C₁₋₆ lower alkyl group optionally substituted at any of the 3-, 4- or 5-position with a halogen atom, a carboxyl group, an alkoxy carbonyl group, and an amino group and R² is a phenyl group optionally having a substituent selected from the group consisting of a C₁₋₆ lower alkyl group, a halogen atom, a carboxyl group, an alkoxy carbonyl group or an amino group, or a pharmaceutically acceptable salt thereof, and a solvent capable of dissolving said pyridone derivative ~~active ingredient~~ in a high concentration of about 10% to about 25% by weight.

2. (original): A pharmaceutical liquid composition according to Claim 1, ~~comprising as the active ingredient~~ wherein the pyridone derivative is a 5-methyl-1-phenyl-2-(1H)-pyridone (Pirfenidone) wherein R¹ is a methyl group at the 5-position and R² is a phenyl group in the formula (I) or a pharmaceutically acceptable salt thereof.

3. **(currently amended):** A pharmaceutical liquid composition according to Claim 1 ~~or 2~~, wherein the solvent is a diethylene glycol monoethyl ether.
4. **(original):** A pharmaceutical liquid composition according to Claim 3, wherein the diethylene glycol monoethyl ether has a purity of 99% or higher.
5. **(currently amended):** A pharmaceutical liquid composition according to ~~any one of~~ Claims 1 ~~to 4~~, further comprising a concentrating agent.
6. **(currently amended):** A pharmaceutical liquid composition according to ~~any one of~~ Claims 1 ~~to 5~~, further containing an antioxidant.
7. **(original):** A pharmaceutical liquid composition according to Claim 6, wherein the antioxidant is an α -tocopherol.
8. **(currently amended):** A pharmaceutical liquid composition according to ~~any one of~~ Claims 1 ~~to 7~~, ~~which is suitable to be administered in the form of an~~ orally, percutaneously, nasally or vaginally preparation or as in the form of a spray, patch, inhalant, injection or intravenous drip.
9. **(currently amended):** A pharmaceutical liquid composition according to ~~any one of~~ Claims 1 ~~to 8~~, having the following components:

<u>Ingredients</u>	<u>% by weight</u>
Pirfenidone	1-25

Diethylene glycol	
monoethyl ether	70-80
Ethanol (95%)	0-10
Polyvinyl pyrrolidone or	
hydroxypropyl cellulose	0-3
Sodium metabisulfite	0.02-2
Methyl or propyl	
paraben	0-0.5
<u>Purified water</u>	<u>0-25</u>

10. (currently amended): A pharmaceutical liquid composition according to ~~any one of~~
Claims 1 ~~to~~ 8, having the following components:

<u>Ingredients</u>	<u>% by weight</u>
Pirfenidone	10-25
Diethylene glycol	
monoethyl ether	75-80
<u>Purified water</u>	<u>0-10</u>

11. (currently amended): A pharmaceutical liquid composition according to ~~any one of~~
Claims 1 ~~to~~ 8, having the following components:

<u>Ingredients</u>	<u>% by weight</u>
Pirfenidone	10-25

AMENDMENT UNDER 37 C.F.R. § 1.111
U.S. Appln. No.: 10/540,422

Atty. Docket No.: Q88273

Diethylene glycol

monoethyl ether 75-80

α -Tocopherol 0.1-0.5

Hydroxypropyl cellulose 0-3

Purified water 0-10 .